Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Propanc Biopharma Inc (PPCB : NSDQ)

• Company Description    Propanc Biopharma, Inc. is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company's products include PRP and PRP-DCM. Propanc Biopharma, Inc., formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $1.76 Daily Weekly Monthly 20 Day Moving Average: 59,323 shares Shares Outstanding: 2.28 (millions) Market Capitalization: $4.01 (millions) Beta: 3.59 52 Week High: $270.25 52 Week Low: $1.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -39.31% -42.27% 12 Week -63.93% -66.66% Year To Date -86.88% -88.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 302 6 Butler Street - Camberwell,C3 3124 AUS ph: 61-03-9882-0780 fax: 61 03 9882 9969 irteam@propanc.com http://www.propanc.com

• General Corporate Information    Officers James Nathanielsz - Chief Executive Office Jeannine Zimmerman - Chief Financial Officer Josef Zelinger - Director Julian Kenyon - Director Joseph Himy - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74346N800 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 10/05/26 Share - Related Items Shares Outstanding: 2.28 Most Recent Split Date: 5.00 (0.04:1) Beta: 3.59 Market Capitalization: $4.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 97.76% vs. Previous Quarter: 6.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -151.28 12/31/25 - -465.18 09/30/25 - -601.01 ROA 03/31/26 - -109.53 12/31/25 - -351.21 09/30/25 - -421.21 Current Ratio 03/31/26 - 2.37 12/31/25 - 2.13 09/30/25 - 2.45 Quick Ratio 03/31/26 - - 12/31/25 - 2.13 09/30/25 - 2.45 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.31 12/31/25 - 17.31 09/30/25 - 28.03 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 9.24 12/31/25 - 8.73 09/30/25 - 0.00

Powered by Zacks Investment Research ©